首页> 外文期刊>Bone marrow transplantation >Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
【24h】

Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma.

机译:外周T细胞淋巴瘤和弥漫性大B细胞淋巴瘤患者自体干细胞移植后的临床结局比较。

获取原文
获取原文并翻译 | 示例
           

摘要

Although patients with T-cell phenotype lymphomas are generally accepted to have worse prognosis than B-cell phenotype lymphomas, the studies comparing outcomes after autologous stem cell transplantation (ASCT) between peripheral T-cell lymphomas (PTCLs) and with diffuse large B-cell lymphoma (DLBCL) are few. In this study, we compared outcomes after ASCT between 23 patients with PTCLs and 54 patients with DLBCL. Univariate analysis showed that the timing of ASCT, complete response (CR) at ASCT, favorable lactate dehydrogenase/performance/stage, low/low-intermediate (L-LI) International Prognostic Index (IPI) and L-LI age-adjusted IPI (aaIPI) at ASCT were significant predictors of both OS and EFS. Multivariate analysis showed that CR and L-LI aaIPI at ASCT were favorable for both OS (hazard ratio (HR), 0.34; 95% CI, 0.14-0.81; P=0.016 and HR, 0.27; 95% CI, 0.12-0.57; P=0.001) and EFS (HR, 0.38; 95% CI, 0.17-0.85; P=0.020 and HR, 0.36; 95% CI, 0.17-0.77; P=0.008). B-cell or T-cell phenotype, however, had no impact on OS (HR, 0.56; 95% CI, 0.27-1.18; P=0.126) or EFS (HR, 0.62; 95% CI, 0.30-1.30; P=0.206). In conclusion, when compared to patients with DLBCL, patients with PTCLs did not have inferior outcomes after ASCT. T-cell phenotype itself may not have an effect on outcomes of PTCL patients who underwent ASCT.
机译:尽管普遍认为T细胞表型淋巴瘤患者的预后比B细胞表型淋巴瘤差,但该研究比较了自体干细胞移植(ASCT)与周围T细胞淋巴瘤(PTCL)和弥漫性大B细胞之间的关系淋巴瘤(DLBCL)很少。在这项研究中,我们比较了23例PTCL和54例DLBCL患者的ASCT结局。单因素分析显示ASCT的时机,ASCT的完全缓解(CR),有利的乳酸脱氢酶/性能/阶段,低/低中级(L-LI)国际预后指数(IPI)和L-LI年龄调整后的IPI( ASCT的aaIPI)是OS和EFS的重要预测指标。多变量分析显示,ASCT的CR和L-LI aaIPI对OS均有利(危险比(HR)为0.34; 95%CI为0.14-0.81; P = 0.016; HR为0.27; 95%CI为0.12-0.57; HR为0.27)。 P = 0.001)和EFS(HR,0.38; 95%CI,0.17-0.85; P = 0.020和HR,0.36; 95%CI,0.17-0.77; P = 0.008)。但是B细胞或T细胞表型对OS(HR,0.56; 95%CI,0.27-1.18; P = 0.126)或EFS(HR,0.62; 95%CI,0.30-1.30; P = 0.206)。总之,与DLBCL患者相比,PTCL的患者在ASCT后没有较差的预后。 T细胞表型本身可能不会对接受ASCT的PTCL患者的预后产生影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号